Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6

Rodger E. Tiedemann, Yuan Xiao Zhu, Jessica Schmidt, Hongwei Yin, Chang Xin Shi, Qiang Que, Gargi Basu, David Azorsa, Louise M. Perkins, Esteban D Braggio, Rafael Fonseca, Peter Leif Bergsagel, Spyro Mousses, Alexander Keith Stewart

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

A paucity of validated kinase targets in human multiple myeloma has delayed clinical deployment of kinase inhibitors in treatment strategies. We therefore conducted a kinome-wide small interfering RNA (siRNA) lethality study in myeloma tumor lines bearing common t(4;14), t(14;16), and t(11;14) translocations to identify critically vulnerable kinases in myeloma tumor cells without regard to preconceived mechanistic notions. Fifteen kinases were repeatedly vulnerable in myeloma cells, including AKT1, AK3L1, AURKA, AURKB, CDC2L1, CDK5R2, FES, FLT4, GAK, GRK6, HK1, PKN1, PLK1, SMG1, and TNK2. Whereas several kinases (PLK1, HK1) were equally vulnerable in epithelial cells, others and particularly G protein - coupled receptor kinase, GRK6, appeared selectively vulnerable in myeloma. GRK6 inhibition was lethal to 6 of 7 myeloma tumor lines but was tolerated in 7 of 7 human cell lines. GRK6 exhibits lymphoid-restricted expression, and from coimmunoprecipitation studies we demonstrate that expression in myeloma cells is regulated via direct association with the heat shock protein 90 (HSP90) chaperone. GRK6 silencing causes suppression of signal transducer and activator of transcription 3 (STAT3) phosphorylation associated with reduction in MCL1 levels and phosphorylation, illustrating a potent mechanism for the cytotoxicity of GRK6 inhibition in multiple myeloma (MM) tumor cells. As mice that lack GRK6 are healthy, inhibition of GRK6 represents a uniquely targeted novel therapeutic strategy in human multiple myeloma.

Original languageEnglish (US)
Pages (from-to)1594-1604
Number of pages11
JournalBlood
Volume115
Issue number8
DOIs
StatePublished - Feb 25 2010

Fingerprint

RNA Interference
Multiple Myeloma
Phosphotransferases
Tumors
Phosphorylation
Cells
Neoplasms
Bearings (structural)
Aurora Kinase A
G-Protein-Coupled Receptor Kinases
HSP90 Heat-Shock Proteins
STAT3 Transcription Factor
Cytotoxicity
Small Interfering RNA
Epithelial Cells
Association reactions
Cell Line
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. / Tiedemann, Rodger E.; Zhu, Yuan Xiao; Schmidt, Jessica; Yin, Hongwei; Shi, Chang Xin; Que, Qiang; Basu, Gargi; Azorsa, David; Perkins, Louise M.; Braggio, Esteban D; Fonseca, Rafael; Bergsagel, Peter Leif; Mousses, Spyro; Stewart, Alexander Keith.

In: Blood, Vol. 115, No. 8, 25.02.2010, p. 1594-1604.

Research output: Contribution to journalArticle

Tiedemann, Rodger E. ; Zhu, Yuan Xiao ; Schmidt, Jessica ; Yin, Hongwei ; Shi, Chang Xin ; Que, Qiang ; Basu, Gargi ; Azorsa, David ; Perkins, Louise M. ; Braggio, Esteban D ; Fonseca, Rafael ; Bergsagel, Peter Leif ; Mousses, Spyro ; Stewart, Alexander Keith. / Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. In: Blood. 2010 ; Vol. 115, No. 8. pp. 1594-1604.
@article{ab40f771d97942e385368e71740edd3e,
title = "Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6",
abstract = "A paucity of validated kinase targets in human multiple myeloma has delayed clinical deployment of kinase inhibitors in treatment strategies. We therefore conducted a kinome-wide small interfering RNA (siRNA) lethality study in myeloma tumor lines bearing common t(4;14), t(14;16), and t(11;14) translocations to identify critically vulnerable kinases in myeloma tumor cells without regard to preconceived mechanistic notions. Fifteen kinases were repeatedly vulnerable in myeloma cells, including AKT1, AK3L1, AURKA, AURKB, CDC2L1, CDK5R2, FES, FLT4, GAK, GRK6, HK1, PKN1, PLK1, SMG1, and TNK2. Whereas several kinases (PLK1, HK1) were equally vulnerable in epithelial cells, others and particularly G protein - coupled receptor kinase, GRK6, appeared selectively vulnerable in myeloma. GRK6 inhibition was lethal to 6 of 7 myeloma tumor lines but was tolerated in 7 of 7 human cell lines. GRK6 exhibits lymphoid-restricted expression, and from coimmunoprecipitation studies we demonstrate that expression in myeloma cells is regulated via direct association with the heat shock protein 90 (HSP90) chaperone. GRK6 silencing causes suppression of signal transducer and activator of transcription 3 (STAT3) phosphorylation associated with reduction in MCL1 levels and phosphorylation, illustrating a potent mechanism for the cytotoxicity of GRK6 inhibition in multiple myeloma (MM) tumor cells. As mice that lack GRK6 are healthy, inhibition of GRK6 represents a uniquely targeted novel therapeutic strategy in human multiple myeloma.",
author = "Tiedemann, {Rodger E.} and Zhu, {Yuan Xiao} and Jessica Schmidt and Hongwei Yin and Shi, {Chang Xin} and Qiang Que and Gargi Basu and David Azorsa and Perkins, {Louise M.} and Braggio, {Esteban D} and Rafael Fonseca and Bergsagel, {Peter Leif} and Spyro Mousses and Stewart, {Alexander Keith}",
year = "2010",
month = "2",
day = "25",
doi = "10.1182/blood-2009-09-243980",
language = "English (US)",
volume = "115",
pages = "1594--1604",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6

AU - Tiedemann, Rodger E.

AU - Zhu, Yuan Xiao

AU - Schmidt, Jessica

AU - Yin, Hongwei

AU - Shi, Chang Xin

AU - Que, Qiang

AU - Basu, Gargi

AU - Azorsa, David

AU - Perkins, Louise M.

AU - Braggio, Esteban D

AU - Fonseca, Rafael

AU - Bergsagel, Peter Leif

AU - Mousses, Spyro

AU - Stewart, Alexander Keith

PY - 2010/2/25

Y1 - 2010/2/25

N2 - A paucity of validated kinase targets in human multiple myeloma has delayed clinical deployment of kinase inhibitors in treatment strategies. We therefore conducted a kinome-wide small interfering RNA (siRNA) lethality study in myeloma tumor lines bearing common t(4;14), t(14;16), and t(11;14) translocations to identify critically vulnerable kinases in myeloma tumor cells without regard to preconceived mechanistic notions. Fifteen kinases were repeatedly vulnerable in myeloma cells, including AKT1, AK3L1, AURKA, AURKB, CDC2L1, CDK5R2, FES, FLT4, GAK, GRK6, HK1, PKN1, PLK1, SMG1, and TNK2. Whereas several kinases (PLK1, HK1) were equally vulnerable in epithelial cells, others and particularly G protein - coupled receptor kinase, GRK6, appeared selectively vulnerable in myeloma. GRK6 inhibition was lethal to 6 of 7 myeloma tumor lines but was tolerated in 7 of 7 human cell lines. GRK6 exhibits lymphoid-restricted expression, and from coimmunoprecipitation studies we demonstrate that expression in myeloma cells is regulated via direct association with the heat shock protein 90 (HSP90) chaperone. GRK6 silencing causes suppression of signal transducer and activator of transcription 3 (STAT3) phosphorylation associated with reduction in MCL1 levels and phosphorylation, illustrating a potent mechanism for the cytotoxicity of GRK6 inhibition in multiple myeloma (MM) tumor cells. As mice that lack GRK6 are healthy, inhibition of GRK6 represents a uniquely targeted novel therapeutic strategy in human multiple myeloma.

AB - A paucity of validated kinase targets in human multiple myeloma has delayed clinical deployment of kinase inhibitors in treatment strategies. We therefore conducted a kinome-wide small interfering RNA (siRNA) lethality study in myeloma tumor lines bearing common t(4;14), t(14;16), and t(11;14) translocations to identify critically vulnerable kinases in myeloma tumor cells without regard to preconceived mechanistic notions. Fifteen kinases were repeatedly vulnerable in myeloma cells, including AKT1, AK3L1, AURKA, AURKB, CDC2L1, CDK5R2, FES, FLT4, GAK, GRK6, HK1, PKN1, PLK1, SMG1, and TNK2. Whereas several kinases (PLK1, HK1) were equally vulnerable in epithelial cells, others and particularly G protein - coupled receptor kinase, GRK6, appeared selectively vulnerable in myeloma. GRK6 inhibition was lethal to 6 of 7 myeloma tumor lines but was tolerated in 7 of 7 human cell lines. GRK6 exhibits lymphoid-restricted expression, and from coimmunoprecipitation studies we demonstrate that expression in myeloma cells is regulated via direct association with the heat shock protein 90 (HSP90) chaperone. GRK6 silencing causes suppression of signal transducer and activator of transcription 3 (STAT3) phosphorylation associated with reduction in MCL1 levels and phosphorylation, illustrating a potent mechanism for the cytotoxicity of GRK6 inhibition in multiple myeloma (MM) tumor cells. As mice that lack GRK6 are healthy, inhibition of GRK6 represents a uniquely targeted novel therapeutic strategy in human multiple myeloma.

UR - http://www.scopus.com/inward/record.url?scp=77949900421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949900421&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-09-243980

DO - 10.1182/blood-2009-09-243980

M3 - Article

C2 - 19996089

AN - SCOPUS:77949900421

VL - 115

SP - 1594

EP - 1604

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -